Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country

Mostly true Certainty of evidence: moderate provisional C-CHM-04

Chemotherapy causes persistent cognitive decline ('chemo fog').

Conclusion: Chemo-related cognitive effects are real but on average small.
  1. Original statement
  2. Scientific assessment
  3. In plain language
  4. Studies on this claim
  5. Regional context
  6. What applies in my country?
  7. References

Original statement

تدهور معرفي مستمر («ضباب الكيماوي»)

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Chemotherapy causes persistent cognitive decline ('chemo fog').

Origin

Source status
Archive editors
Attribution
Archive editors (rule page summary/narrative)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Claimed mechanism

Neurotoxicity of cytotoxic drugs

Claimed health effect

Cognitive impairment

Population concerned

Breast cancer and lymphoma survivors

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Persistent cognitive decline confirmed by Ahles and Jim.

2. What is demonstrably correct?

Long-term survivors after chemotherapy scored lower on tests, with a subgroup clearly affected (39% vs 14% in lowest quartile; A-CHM-09). A meta-analysis found deficits >=6 months after chemotherapy in verbal (g=-0.19) and visuospatial ability (g=-0.27) (A-CHM-10).

3. What is wrong or exaggerated?

'Persistent cognitive decline' overstates the average: deficits are small and limited to two of eight domains; Ahles et al. note only a subgroup has long-term deficits.

4. What remains unclear?

Who is at risk and whether effects improve over time.

5. Which studies support it?

A-CHM-09, A-CHM-10.

6. Which studies contradict it?

A-CHM-10 (small average magnitude).

7. What applies to Germany and Europe?

Cognitive rehabilitation offers exist in some European survivorship programmes (not audited).

8. What is known about Egypt?

No data reviewed.

9. What practical conclusion is appropriate?

Report thinking or memory problems; most survivors are mildly affected.

Assessment details

Rationale for certainty of evidence

Effect exists in a meta-analysis and earlier studies, but average magnitude is small and limited to some domains; heterogeneous studies.

Source quality

Correctly cited studies; overstated summary.

Regional transferability

High.

Individual exceptions

Subgroup with larger deficits.

Regional scope of the claim
general (biological/medical)
Last reviewed
25 October 2026 provisional

In plain language

Some people notice problems with memory or concentration after chemotherapy. Studies confirm small average differences in some thinking skills, while a minority is more affected. This is real and deserves attention, but it does not mean that everyone has lasting decline.

Studies on this claim

Studies supporting the claim (1)

  • Some long-term survivors show memory problems after chemotherapy

    Ahles TA et al.. J Clin Oncol 2002 · PMID 11786578 · DOI 10.1200/JCO.2002.20.2.485
    Cross-sectional studycited by the Tayebat archiveabstract only checked

    39% of chemotherapy-treated vs 14% of locally treated survivors scored in the lowest quarter on memory/thinking tests.

    Cognitive deficits in a subgroup

    Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare cognition by treatment.

    How was the study done?

    Cross-sectional testing.

    How many people, animals or samples were studied?

    128 survivors (sum of four reported groups: 35+36+35+22).

    What was actually found?

    Lower verbal memory and psychomotor scores.

    How large was the observed effect?

    39% vs 14% lowest quartile.

    What do the results mean in everyday life?

    Some survivors notice thinking problems; support exists.

    What are the study's limitations?

    Small, no baseline.

    What does it say about Elawady's specific claim?

    Supports a subgroup effect.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    That all patients suffer lasting decline.

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (1)

  • Chemotherapy-related thinking problems are small on average

    Jim HS et al.. J Clin Oncol 2012 · PMID 22927526 · DOI 10.1200/JCO.2011.39.5640
    Meta-analysiscited by the Tayebat archiveabstract only checked★ key study

    Breast-cancer survivors performed slightly worse in two of eight areas of thinking.

    Small average deficits

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pool studies on cognition after chemo.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    17 studies, 807 patients.

    What was actually found?

    Small deficits in verbal and visuospatial ability.

    How large was the observed effect?

    g -0.19 and -0.27.

    What do the results mean in everyday life?

    Most survivors are only mildly affected, some more.

    What are the study's limitations?

    Heterogeneous studies.

    What does it say about Elawady's specific claim?

    Limits 'persistent decline'.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Individual risk.

    Scientific details →

Regional context

Germany / EU

Cognitive rehabilitation offers exist in some European survivorship programmes (not audited).

Egypt

No data reviewed.

What applies in my country?

General scientific assessment

Mostly true Chemo-related cognitive effects are real but on average small.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.. Ahles TA et al.. J Clin Oncol 2002 · PMID 11786578 · DOI 10.1200/JCO.2002.20.2.485
  2. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.. Jim HS et al.. J Clin Oncol 2012 · PMID 22927526 · DOI 10.1200/JCO.2011.39.5640

← Back to overview